Moleculin Biotech, Inc.
- MBRX
- NASDAQ
- Biotechnology
- Anticancer/Antiviral Drugs
- Clinical-Stage Pharma
$0.26
Today −6.60%Quote Oct 19, 2026, 07:38 PM UTC
−64.05%over the last month
Max drawdown −64.1%From 1-month high −64.1%3 months −86.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
17
Founded
2015
Market value
$5.1M
Quote Oct 19
Resistance
$0.33
24.3% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MBRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free